Skip to Content

Sartorius Stedim Biotech SA

DIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€916.00RqplZrwgrqnjr

Sartorius Stedim Reset in 2023 Tougher Than Anticipated

Business Strategy and Outlook

Sartorius Stedim Biotech, the bioprocess subsidiary of Sartorius AG, is a leading provider of single-use biopharmaceutical fermentation and fluid management solutions. It offers services ranging from early-stage consultancy to commercial-scale equipment. After an initial period of consultation and customer-partnered engineering work, Sartorius does custom installation of biomanufacturing systems for its customers, consisting of bioreactors, fermenters, and cell analysis systems. This equipment has high disposable consumable requirements because customized filters are often used for disinfection due to the sensitivity of biochemical processes. The company’s proven expertise in single-use technology and the regulation-validated nature of biomanufacturing gives Sartorius an attractive razor/razor blade model.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of DIM so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center